Skip to main content

Site notifications

ENRYLAZE Jazz Pharmaceuticals ANZ Pty Ltd

Product name
ENRYLAZE
Accepted date
Oct-2023
Active ingredients
crisantaspase
Proposed indication
For treatment of acute lymphoblastic leukaemia and lymphoblastic leukaemia.
Application type
A (new medicine)
Publication date
Oct-2023
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site